Revolution Medicines price target raised to $162 from $140 at RBC Capital

RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $162 from $140 and keeps an Outperform rating on the shares. The firm is citing the company’s successful results from their critical RASolute-302 study while noting that its management has reiterated their enthusiasm for the asset and the company’s leadership in the RAS inhibitor space, the analyst tells investors in a research note.